Clinical response versus placebo   Median OR (95% CrI) SUCRA Ulnar-I 128.30 (9.76 to 2299.00) 98%** DI 7.00 (0.53 to 118.80) 46% PI 8.85 (3.00 to 33.15) 54%   Change in symptom severity scale versus placebo   Median MD (95% CrI) SUCRA Ulnar-I -1.16 (-1.95 to -0.38) 95%** Ulnar-O -0.78 (-1.43 to -0.16) 64% PI -0.58 (-0.95 to -0.22) 40%   Change in functional status scale versus placebo   Median MD (95% CrI) SUCRA Ulnar-I -0.74 (-2.00 to 0.52) 78%** Ulnar-O -0.63 (-1.67 to 0.43) 67% PI -0.46 (-1.11 to 0.21) 48%

OR = odds ratio, MD = mean difference, CrI = credible interval, SUCRA = surface under the cumulative ranking curve, DI = distal approach corticosteroid injection, PI = proximal approach corticosteroid injection, Ulnar-I = ultrasound-guided in-plane injection, Ulnar-O = ultrasound-guided out-plane injection.**The best injection approach.

Table 1: Summary results of network meta-analysis: posterior ORs or MDs with their 95% credible intervals of all treatment strategies and SUCRA values (Adapted from Chen et al.).